The treatment of patients with moderate to severe Crohn's disease [CD] is still challenging.
Therapeutic options include steroids, immunosuppressants, anti-TNFα agents, vedolizumab …

Abstract Background and Aims Many observational studies on the use of vedolizumab [VDZ]
in patients with Crohn's disease [CD] and ulcerative colitis [UC] have been published in the …

Abstract Background and Aims This study compares the effectiveness of different biologic
therapies and sequences in patients with inflammatory bowel disease [IBD] using real-world …

Despite the enlarging therapeutic armamentarium in inflammatory bowel disease (IBD), it is
still plagued by a therapeutic ceiling, with response to therapy in clinical trials typically not …

Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic
after vedolizumab (VDZ) failure has not yet been described. Aims and Methods: In this …

Background Vedolizumab is approved for the treatment of moderately to severely active
Crohn's disease (CD). Real‐world evidence is essential for understanding the effectiveness …

Background Many patients with inflammatory bowel disease (IBD) have signs or symptoms
of active disease despite multiple treatment attempts. This emerging concept is defined as …

Introduction: Limited data exist on the efficacy of combination therapy with ustekinumab and
budesonide in patients with Crohn's disease. Our objective was to compare the clinical …

Abstract Background The effectiveness of Ustekinumab (UST) and Vedolizumab (VDZ) in
patients with Crohn's disease (CD) as third-line biologic therapies is unclear. Aims We …

In the last 20 years, the treatment and management of patients with Crohn's disease (CD)
and ulcerative colitis (UC) have been revolutionized by the introduction of biological …